Swk Holdings CORP 8-K filings

SWK Holdings Corporation has finalized its merger with Runway Growth Finance Corp., resulting in the company becoming a wholly-owned subsidiary of RWAY.

SWK Holdings Corporation amended its Credit Agreement, reducing aggregate commitments to $7.5 million and modifying financial covenants.

SWK Holdings Corporation has amended its Credit Agreement, significantly reducing its aggregate commitments from $60 million to $10 million, effective December 4, 2025.

SWK Holdings Corporation announced early termination of the Hart-Scott-Rodino waiting period for its merger with Runway Growth Finance Corp., satisfying a key closing condition.

SWK Holdings Corporation announced robust third-quarter 2025 financial results, marked by significant net income growth and a planned merger with Runway Growth Finance Corp.

SWK Holdings Corporation has entered into a definitive merger agreement with Runway Growth Finance Corp., offering shareholders a mix of cash and stock consideration.

Runway Growth Finance Corp. announced a definitive merger agreement to acquire SWK Holdings Corporation, expanding its healthcare and life sciences portfolio and projecting mid-single-digit NII accretion.

SWK Holdings Corporation announced the full repayment of its loan to Elutia, Inc., resulting in $27.8 million in proceeds and expected incremental income.

SWK Holdings Corporation announced its second quarter 2025 financial results, highlighting strategic divestitures of its royalty portfolio and MOD3 assets, alongside a significant special dividend payment to shareholders.

SWK Holdings Corporation has completed the sale of substantially all assets of its MOD3 Pharma contract manufacturing, formulation, and development services business to AptarGroup, Inc. for approximately $6.9 million.

SWK Holdings Corporation announced that its stockholders approved an amendment to the 2010 Equity Incentive Plan, extending its termination date to June 13, 2030, and re-elected three directors at the 2025 Annual Meeting.

SWK Holdings Corporation's Board of Directors has authorized a share repurchase program of up to $10 million, effective from May 19, 2025, to May 19, 2026.

SWK Holdings announces its Q1 2025 results, showcasing a focus on shareholder returns through strategic financings, royalty monetizations, and share repurchases.

SWK Holdings Corporation announced a significant increase in GAAP net income and finance receivables segment adjusted non-GAAP net income for the first quarter of 2025, alongside strategic portfolio adjustments.

SWK Holdings Corporation finalizes the sale of its royalty portfolio to SCOF SPV I, LP for $34 million and declares a special cash dividend of $4 per share.

SWK Holdings Corporation announces the monetization of its royalty portfolio through the sale of its performing royalty portfolio and the buyout of the Iluvien royalty, totaling approximately $51.3 million, and plans to declare a cash dividend to stockholders.

SWK Holdings presents its strategy of providing custom financing solutions to commercial-stage healthcare companies and royalty owners, targeting a 10% CAGR in book value per share.

SWK Holdings announces a significant increase in revenue and net income for the fourth quarter of 2024, driven by growth in both its Finance Receivables and Pharmaceutical Development segments.

SWK Holdings Corporation released an investor presentation detailing its financial performance, strategic focus on life science financing, and value creation strategies.

SWK Holdings saw a revenue increase in Q3 2024, but net income decreased compared to the same period last year, with notable growth in finance receivables and book value per share.

Marcus Pennington resigned from the Board of Directors of SWK Holdings Corporation, effective October 1, 2024.

SWK Holdings released an investor presentation detailing its financial performance, strategic focus on life science financing, and plans for future growth.

SWK Holdings saw a revenue increase in the second quarter of 2024, but loan impairments led to a decrease in non-GAAP net income for the finance receivables segment.

SWK Holdings provided a corporate update highlighting recent achievements, including portfolio company successes and key personnel changes.

SWK Holdings Corporation has appointed Adam Rice as its new Chief Financial Officer and promoted Courtney Baker to Controller, effective July 3, 2024.

SWK Holdings Corporation held its 2024 Annual Meeting of Stockholders, where directors were elected, the appointment of auditors was ratified, and executive compensation was approved on an advisory basis.

SWK Holdings Corporation authorized a $10 million share repurchase program and released an investor presentation highlighting its financial performance and strategic initiatives.

SWK Holdings saw a significant increase in revenue for Q1 2024, but this was offset by a substantial loan impairment, leading to a decrease in net income compared to the same period last year.

SWK Holdings Corporation released an investor presentation detailing its financial performance, strategic focus on life science financing, and the recent exclusive option agreement for its Enteris BioPharma subsidiary.

SWK Holdings Corporation announced its fourth quarter 2023 financial results, highlighting a strategic shift towards its core finance business and a new agreement for its Enteris assets.